Loading company…
OrigoBio develops therapeutic solutions using intelligent nanovesicle technology.
Founded in 2022 and based in Hangzhou, China, OrigoBio develops therapeutic solutions using its NCVx intelligent nanovesicle platform. Its work targets tissue repair and regenerative medicine. In July 2026, it raised Series A+ funding from Puhua Capital, Ningbo Danbei Investment Management Partnership, HangZhou Capital, Zhejiang University Holding and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in